<DOC>
	<DOCNO>NCT02259348</DOCNO>
	<brief_summary>This pilot phase II trial study well new reduce intensity condition regimen include haploidentical donor NK cell follow infusion selectively T-cell deplete progenitor cell graft work treat young patient hematologic malignancy return respond treatment prior transplant . Giving chemotherapy natural killer cell donor progenitor cell transplant may help stop growth cell bone marrow , include normal blood-forming cell ( progenitor cell ) cancer cell . It may also stop patient 's immune system reject donor 's cell . When healthy progenitor cell relate donor infused patient make red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell ( call graft-versus-host disease ) . Removing specific T cell donor cell transplant may prevent .</brief_summary>
	<brief_title>Repeat Transplantation Relapsed Refractory Hematologic Malignancies Following Prior Transplantation</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : - To estimate engraftment day +42 post-transplant patient receive CD45RA-depleted haploidentical donor progenitor cell transplantation follow reduce intensity condition regimen include haploidentical natural killer ( NK ) cell . SECONDARY OBJECTIVES : - Estimate incidence malignant relapse , event-free survival , overall survival one-year post-transplantation . - Estimate incidence severity acute chronic ( GvHD ) . - Estimate rate transplant relate mortality ( TRM ) first 100 day transplantation . Blood progenitor cell collect adult donor use transplantation . Donor cell process filtered laboratory St. Jude use machine call CliniMACS™ device , later infuse ( transplant ) participant his/her vein . Participants undergo condition regimen begin Day 21 prior progenitor cell transplantation include chemotherapy medication natural killer cell preparation transplantation . They receive T-cell deplete HPC transplant follow CD45RA-depleted HPC transplant follow day .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Sarcoma , Myeloid</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Age le equal 21 year . One follow hematologic malignancy relapse remains refractory prior allogeneic hematopoietic cell transplant ( HCT ) : ALL , AML , Myeloid Sarcoma , CML , Juvenile myelomonocytic leukemia ( JMML ) , myelodysplastic syndrome ( MDS ) , nonHodgkin lymphoma ( NHL ) Has suitable single haplotype match ( ≥ 3 6 ) family member donor . Does active malignancy one transplant indicate . If prior central nervous system ( CNS ) leukemia , must treat CNS complete remission ( CR ) Does current uncontrolled bacterial , fungal , viral infection . Patient must fulfill pretransplant evaluation : Left ventricular ejection fraction &gt; 40 % , shorten fraction ≥ 25 % . Creatinine clearance ( CrCl ) glomerular filtration rate ( GFR ) ≥ 50 ml/min/1.73m2 . Forced vital capacity ( FVC ) ≥ 40 % predict value ; pulse oximetry ≥ 92 % room air patient unable perform pulmonary function test . Karnofsky Lansky ( agedependent ) performance score ≥ 50 ( See Appendix A ) . Bilirubin ≤ 3 time upper limit normal age . Alanine aminotransferase ( ALT ) ≤ 5 time upper limit normal age . Not pregnant . If female child bear potential , must confirm negative serum urine pregnancy test within 14 day prior enrollment . Not breast feed DONOR : At least single haplotype match ( ≥ 3 6 ) family member DONOR : At least 18 year age . DONOR : HIV negative . DONOR : Not pregnant confirm negative serum urine pregnancy test within 14 day prior enrollment ( female ) . DONOR : Not breast feed . DONOR : Regarding donation eligibility , identify either : Completed process donor eligibility determination outline 21 CFR 1271 agency guidance ; OR Does meet 21 CFR 1271 eligibility requirement , declaration urgent medical need complete principal investigator physician subinvestigator per 21 CFR 1271 .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hematological malignancy</keyword>
	<keyword>Allogeneic hematopoietic cell transplant</keyword>
	<keyword>Refractory hematologic malignancy</keyword>
	<keyword>Relapsed hematologic malignancy</keyword>
</DOC>